KP1077 Demonstrates Safety in Idiopathic Hypersomnia Patients
The phase 2 trial explored the safety and efficacy of KP1077 in reducing daytime sleepiness and sleep inertia, with results presented at SLEEP 2024.
The phase 2 trial explored the safety and efficacy of KP1077 in reducing daytime sleepiness and sleep inertia, with results presented at SLEEP 2024.